SAN DIEGO--(BUSINESS WIRE)--Ablexis, LLC (“Ablexis”), a biopharmaceutical company focused on licensing its AlivaMab® Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC (“ADS”), a leader in the discovery of superior antibody-based therapeutics, which together are leading providers of solutions for the discovery of superior antibody-based therapeutics, announced an expansion of platforms and capabilities in antibody drug discovery and engineering. These innovative new offerings include:. Molecularly diverse panels of lead-quality antibodies ready for reformatting into multispecific formats of the partner’s choice, including a large panel of T-cell-engaging CD3 antibodies that potently eliminate cancer cells with minimal cytokine release

SAN DIEGO--(BUSINESS WIRE)--AlivaMab Discovery Services (“ADS”), a leader in the discovery of superior antibody-based therapeutics, announced that Larry Green has reassumed the role of Chief Executive Officer, effective immediately. He assumes the role from Justin Mika. Dr. Green, who brings over 30 years’ experience in antibody drug discovery and development, is the founding Chief Executive Officer of ADS and has served as Executive Chair since May 2020. He continues in his role as CEO of Ablexis, LLC. “We thank Justin for his leadership in growing ADS during the past two years,” said Dr. Green, Chief Executive Officer at AlivaMab Discovery Services. “I look forward to continuing that growth, including new offerings in antibody drug discovery and engineering, and to working closely with our expanding roster of partners, leveraging the synergy of ADS’ integrated fully human antibody drug discovery and engineering platforms with the ADS team’s experience and know-how in antibody drug discovery.”

In addition, Almirall will collaborate with AlivaMab Discovery Services to conduct the research, leveraging ADS’ expertise in antibody drug discovery and engineering using the AlivaMab Mouse technology, a state-of-art platform for the generation of human therapeutic antibodies.